Investors with a lot of money to spend have taken a bearish stance on Moderna MRNA.
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 13 options trades for Moderna.
This isn't normal.
The overall sentiment of these big-money traders is split between 46% bullish and 53%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $43,750, and 12, calls, for a total amount of $888,206.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $60.0 for Moderna over the recent three months.
Analyzing Volume & Open Interest
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Moderna's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale activity within a strike price range from $20.0 to $60.0 in the last 30 days.
Moderna Option Activity Analysis: Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | CALL | TRADE | BULLISH | 03/21/25 | $2.95 | $2.37 | $2.8 | $40.00 | $140.0K | 1.2K | 512 |
| MRNA | CALL | SWEEP | BEARISH | 02/21/25 | $0.8 | $0.74 | $0.74 | $45.00 | $118.1K | 5.4K | 2.2K |
| MRNA | CALL | TRADE | BEARISH | 12/18/26 | $24.2 | $23.5 | $23.5 | $20.00 | $117.5K | 137 | 50 |
| MRNA | CALL | SWEEP | BEARISH | 03/21/25 | $2.2 | $2.17 | $2.14 | $45.00 | $108.0K | 6.5K | 1.4K |
| MRNA | CALL | SWEEP | BEARISH | 03/21/25 | $2.22 | $2.19 | $2.19 | $45.00 | $70.2K | 6.5K | 1.8K |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Present Market Standing of Moderna
- With a trading volume of 3,544,180, the price of MRNA is up by 8.89%, reaching $39.08.
- Current RSI values indicate that the stock is may be approaching overbought.
- Next earnings report is scheduled for 29 days from now.
What The Experts Say On Moderna
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $67.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Moderna, which currently sits at a price target of $38. * Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Moderna, targeting a price of $96.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with Benzinga Pro for real-time alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
